Skip to main content
OpenTrials

Clinical trial condition

Stage IIIC Cutaneous Melanoma AJCC v7

Explore clinical trials studying Stage IIIC Cutaneous Melanoma AJCC v7. Study availability and eligibility vary by location and protocol.

22 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

Stage IIIC Cutaneous Melanoma AJCC v7 trial results

Completed

A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma

NCT02129075

Conditions
Cutaneous Melanoma, Eye Diseases, Eye Neoplasms, +25 more
Locations
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone New York, United States
  • Mount Sinai Hospital New York, United States
  • Duke University Medical Center Durham, North Carolina, United States
View Trial Details
Completed

Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

NCT01258855

Conditions
Melanoma, Metastatic Melanoma, Neoplasms, +16 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • City of Hope South Pasadena South Pasadena, California, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
View all 21 locations
View Trial Details
Completed

Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer

NCT01727076

Conditions
Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +47 more
Locations
  • Stanford Cancer Institute Palo Alto Palo Alto, California, United States
  • National Institutes of Health Clinical Center Bethesda, Maryland, United States
  • University of Minnesota/Masonic Cancer Center Minneapolis, Minnesota, United States
  • Seattle Cancer Care Alliance Seattle, Washington, United States
View Trial Details
Active, Not Recruiting

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

NCT01274338

Conditions
Melanoma, Melanoma of Unknown Primary, Neoplasms, +14 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Providence Hospital Mobile, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Alaska Regional Hospital Anchorage, Alaska, United States
View all 938 locations
View Trial Details
Active, Not Recruiting

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

NCT01134614

Conditions
Advanced Melanoma, Melanoma, Metastatic Melanoma, +18 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Stanford Cancer Institute Palo Alto Palo Alto, California, United States
  • VA Palo Alto Health Care System Palo Alto, California, United States
  • Eisenhower Medical Center Rancho Mirage, California, United States
View all 257 locations
View Trial Details
Active, Not Recruiting

Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

NCT02965716

Conditions
Advanced Melanoma, Melanoma, Neoplasms, +17 more
Locations
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • CTCA at Western Regional Medical Center Goodyear, Arizona, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
View all 20 locations
View Trial Details

Related conditions